A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

BACKGROUND: In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to monotherapy. In Japan, three different once-da...

Descripción completa

Detalles Bibliográficos
Autores principales: Muraki, Masato, Kunita, Yuki, Shirahase, Ken, Yamazaki, Ryo, Hanada, Soichiro, Sawaguchi, Hirochiyo, Tohda, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805049/
https://www.ncbi.nlm.nih.gov/pubmed/33441146
http://dx.doi.org/10.1186/s12890-021-01403-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805049/
https://www.ncbi.nlm.nih.gov/pubmed/33441146
http://dx.doi.org/10.1186/s12890-021-01403-y

Ejemplares similares